March 22, 2021: We support this update, strengthened by new evidence, maintaining the 2014 “B” recommendation that there is moderate certainty of a substantial net benefit for the use of low-dose aspirin as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.
Read More »Tag: pregnancy
Birth Control Apps Show the Contradictions in FDA Device Oversight
The Verge, March 17, 2021: The FDA has allowed a second digital birth control app to be sold in the U.S. Neither Natural Cycles nor Clue were tested in clinical trials. NCHR asks how safe and effective are they, and are women being misled?
Read More »NCHR’s Comments on the USPSTF’s Recommendation on Screening for Bacterial Vaginosis in Pregnant Persons
November 4, 2019. Given the lack of convincing evidence that screening for bacterial vaginosis leads to a clinical benefit, NCHR supports the USPSTF’s caution in making a recommendation to screen for bacterial vaginosis in pregnant persons to prevent preterm delivery.
Read More »NCHR Comments on FDA’s Guidance on Post-Approval Pregnancy Safety Studies
June 28, 2019: NCHR public comment urges FDA to require safety studies of drugs taken during or after pregnancy that include women of all races, ethnicities and access to insurance. FDA should require better tracking of medication risks, and ensuring that research represents all races, ethnicities, and insurance types (including uninsured women and those on Medicaid). With 9 out of 10 pregnant women taking medications, we need better safety data to protect both mothers and babies.
Read More »Trying to Get Pregnant or Trying to Avoid it? Now, There Are Apps for Both!
Digital birth control apps are becoming more common. The FDA has now cleared two apps: Natural Cycles and Clue for preventing pregnancy. Read more about why these apps are unreliable for women looking to avoid pregnancy.
Read More »